Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2

EMBO Journal

Volumn 25, Issue 20, 2006, Pages 4763-4772

  Funakoshi Tago, Megumi ^a   Pelletier, Stephane ^a   Matsuda, Tadashi ^b   Parganas, Evan ^a   Ihle, James N ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Autophosphorylation; Cytokine receptor; FERM domain; Jak kinases; Jak2

Indexed keywords

CYTOKINE; ERYTHROPOIETIN RECEPTOR; GROWTH HORMONE RECEPTOR; JANUS KINASE 2; RECEPTOR; THROMBOPOIETIN RECEPTOR;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DISSOCIATION; EMBRYO; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; CYTOKINES; HUMANS; JANUS KINASE 2; LIGANDS; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION;

EID: 33750221616     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/sj.emboj.7601365     Document Type: Article

References (43)

1. Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C (2004) Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 24: 4955-4967
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061
3. Boggon TJ, Li Y, Manley PW, Eck MJ (2005) Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106: 996-1002
4. Briscoe J, Rogers NC, Witthuhn BA, Watling D, Harpur AG, Wilks AF, Stark GR, Ihle JN, Kerr IM (1996) Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO J 15: 799-809
5. Cacalano NA, Migone TS, Bazan F, Hanson EP, Chen M, Candotti F, O'Shea JJ, Johnston JA (1999) Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J 18: 1549-1558
6. Chen M, Cheng A, Chen YQ, Hymel A, Hanson EP, Kimmel L, Minami Y, Taniguchi T, Changelian PS, O'Shea JJ (1997) The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci USA 94: 6910-6915
7. Duan C, Yang H, White MF, Rui L (2004) Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose intolerance. Mol Cell Biol 24: 7435-7443
8. Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers Jr MG (2004) Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 24: 4968-4978
9. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN (1997) Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 17: 2497-2501
10. Frank SJ, Yi W, Zhao Y, Goldsmith JF, Gilliland G, Jiang J, Sakai I, Kraft AS (1995) Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J Biol Chem 270: 14776-14785
11. Giordanetto F, Kroemer RT (2002) Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 15: 727-737
12. Girault JA, Labesse G, Mornon JP, Callebaut I (1998) Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Mol Med 4: 751-769
13. Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N (1995) Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J 14: 2857-2865
14. He K, Wang X, Jiang J, Guan R, Bernstein KE, Sayeski PP, Frank SJ (2003) Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol Endocrinol 17: 2211-2227
15. Hilkens CM, Is'harc H, Lillemeier BF, Strobl B, Bates PA, Behrmann I, Kerr IM (2001) A region encompassing the FERM domain of Jak1 is necessary for binding to the cytokine receptor gp130. FEBS Lett 505: 87-91
16. Ihle JN (1995) Cytokine receptor signalling. Nature 377: 591-594
17. Ihle JN (1996) Janus kinases in cytokine signalling. Philos Trans Roy Soc London B 351: 159-166
18. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148
19. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-2168
20. Kampa D, Burnside J (2000) Computational and functional analysis of the putative SH2 domain in Janus Kinases. Biochem Biophys Res Commun 278: 175-182
21. Kohlhuber F, Rogers NC, Watling D, Feng J, Guschin D, Briscoe J, Witthuhn BA, Kotenko SV, Pestka S, Stark GR, Ihle JN, Kerr IM (1997) A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol 17: 695-706
22. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790
23. Krieg J, Hunter T (1992) Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin. J Biol Chem 267: 19258-19265
24. Kurzer JH, Argetsinger LS, Zhou YJ, Kouadio JL, O'Shea JJ, Carter-Su C (2004) Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol Cell Biol 24: 4557-4570
25. Leonard WJ, O'Shea JJ (1998) Jaks and STATs: biological implications. Annu Rev Immunol 16: 293-322
26. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397
27. Luo H, Hanratty WP, Dearolf CR (1995) An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects. EMBO J 14: 1412-1420
28. Matsuda T, Feng J, Witthuhn BA, Sekine Y, Ihle JN (2004) Determination of the transphosphorylation sites of Jak2 kinase. Biochem Biophys Res Commun 325: 586-594
29. Miura O, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, Aoki N (1994) Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Blood 84: 1501-1507
30. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93: 397-409
31. O'Shea JJ, Notarangelo LD, Johnston JA, Candotti F (1997) Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J Clin Immunol 17: 431-447
32. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395
33. Quelle FW, Wang D, Nosaka T, Thierfelder WE, Stravopodis D, Weinstein Y, Ihle JN (1996) Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol 16: 1622-1631
34. Saharinen P, Silvennoinen O (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277: 47954-47963
35. Saharinen P, Takaluoma K, Silvennoinen O (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 20: 3387-3395
36. Saharinen P, Vihinen M, Silvennoinen O (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14: 1448-1459
37. Smith WJ, Nassar N, Bretscher A, Cerione RA, Karplus PA (2003) Structure of the active N-terminal domain of Ezrin. J Biol Chem 278: 4949-4956
38. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood 106: 1207-1209
39. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227-236
40. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F (2001) Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106: 745-757
41. Zang H, Sato K, Nakajima H, McKay C, Ney PA, Ihle JN (2001) The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis. EMBO J 20: 3156-3166
42. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280: 22788-22792
43. Zhou YJ, Chen M, Cusack NA, Kimmel LH, Magnuson KS, Boyd JG, Lin W, Roberts JL, Lengi A, Buckley RH, Geahlen RL, Candotti F, Gadina M, Changelian PS, O'Shea JJ (2001) Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell 8: 959-969